David Stamler, M.D., Chief Executive Officer of Alterity, commented, “We are excited to presentthe positive topline data along with new analyses from our ATH434-201 clinical trial via an oralpresentation at AAN, one of the premier global neurology meetings. In addition, data will bepresented on the use of wearable sensor technology to assess patient outcomes, an importantcomponent of evaluating novel treatments for individuals with MSA.”
need help ” new analyses from our ATH 434-201 “ where is it ??
ATH Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)